Prague Med. Rep. 2024, 125, 232-238
https://doi.org/10.14712/23362936.2024.21
A Rare Case of Neuromyelitis Optica Spectrum Disorder Secondary to Primary Sjögren’s Syndrome in an Older Woman
References
1. , T., Takahashi, T., Fujihara, K., Misu, T., Fujimori, J., Takai, Y., Nishiyama, S., Abe, M., Ishii, T., Aoki, M., Nakashima, I. (2021) Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J. Neurol. 268(5), 1938–1944.
<https://doi.org/10.1007/s00415-020-10377-6>
2. , E. L. (1993) Neurologic disease in Sjögren’s syndrome: Mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum. Dis. Clin. North Am. 19(4), 869–908.
<https://doi.org/10.1016/S0889-857X(21)00211-8>
3. , A. G. (2018) Medication-induced xerostomia and hyposalivation in the elderly: Culprits, complications, and management. Drugs Aging 35(10), 877–885.
<https://doi.org/10.1007/s40266-018-0588-5>
4. , A. L., Samuels, M. A. (2014) The neurology of Sjögren’s syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract. Neurol. 14, 14–22.
<https://doi.org/10.1136/practneurol-2013-000651>
5. Fox, R. I. (2011) Extraglandular manifestations of Sjögren’s syndrome (SS): Dermatologic, arthritic, endocrine, pulmonary, cardiovascular, gastroenterology, renal, urology, and gynecologic manifestations. In: Sjögren’s Syndrome. Fox, R., Fox, C., pp. 285–316, Springer, New York.
6. , G., La Rocca, G., Chatzis, L. G., Ferro, F., Navarro Garcia, I. C., Cafaro, G., Goules, A. V., Bartoloni, E., Baldini, C. (2023) Impact of gender and age at onset on Sjögren’s syndrome presentation and outcome: State of the art. Clin. Exp. Rheumatol. 41(12), 2547–2554.
7. , Y., Sun, Q., Yi, F., Yao, L., Tian, Y., Tang, H., Luo, M., Xie, N., Wang, Z., Liao, X., Zhou, L., Xu, H., Zhou, Y. (2022) Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder. Front. Immunol. 13, 1056944.
<https://doi.org/10.3389/fimmu.2022.1056944>
8. , S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Kleiter, I., Klotz, L., Krumbholz, M., Kümpfel, T., Paul, F., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J. P., Bergh, F. T., Tumnani, H., Wildemann, B.; Neuromyelitis Optica Study Group (NEMOS) (2023) Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J. Neurol. 270(7), 3341–3368.
<https://doi.org/10.1007/s00415-023-11634-0>
9. , B., Dion, M. R., Jurasic, M. M., Gibson, G., Jones, J. A. (2012) Xerostomia and salivary hypofunction in vulnerable elders: Prevalence and etiology. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114(1), 52–60.
<https://doi.org/10.1016/j.oooo.2011.11.014>
10. , M. (2017) Neurologic manifestations of primary Sjögren syndrome. Rheum. Dis. Clin. North Am. 43(4), 519–529.
<https://doi.org/10.1016/j.rdc.2017.06.002>
11. , S. S., Baer, A. N. (2017) Neurological complications of Sjögren’s syndrome: Diagnosis and management. Curr. Treatm. Opt. Rheumatol. 3(4), 275–288.
<https://doi.org/10.1007/s40674-017-0076-9>
12. , E., Ciudad-Gutiérrez, P., Rodríguez-Ramallo, H., Sánchez-Fidalgo, S., Santos-Ramos, B., Villalba-Moreno, A. M. (2022) Association between anticholinergic activity and xerostomia and/or xerophthalmia in the elderly: Systematic review. BMC Pharmacol. Toxicol. 23(1), 94.
<https://doi.org/10.1186/s40360-022-00637-8>
13. , S., Doosti, R., Shahmohammadi, A., Mohammadianinejad, S. E., Sahraian, M. A., Azimi, A. R., Harirchian, M. H., Asgari, N., Naser Moghadasi, A. (2019) Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult. Scler. Relat. Disord. 27, 350–363.
<https://doi.org/10.1016/j.msard.2018.11.008>
